CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS

被引：0
|
作者：
Hiken, Eliah J. [1 ]
Poweleit, Ethan A. [1 ]
Keane, Corey [1 ]
Desta, Zeruesenay [1 ]
Strawn, Jeffrey R. [1 ]
Ramsey, Laura B.
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY | 2023年 / 62卷 / 10期
关键词：
D O I：
10.1016/j.jaac.2023.09.140
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
2.53
引用
收藏
页码：S197 / S197
页数：1
相关论文
共 50 条
  • [21] On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.
    Brockmöller, J
    Kirchheiner, J
    Henckel, H
    Meineke, I
    Roots, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P67 - P67
  • [22] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [23] Influence of CYP2D6 phenotype on the Pharmacokinetics-Pharmacodynamics of tramadol
    Percevault, S.
    De La Gastine, B.
    Varin, L.
    Richard, N.
    Loilier, M.
    Bleyzac, N.
    Bourguignon, L.
    Lelong-Boulouard, V.
    Goutelle, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 43 - 44
  • [24] Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6
    Raimundo, S
    Fischer, R
    Eichelbaum, M
    Griese, EU
    Schwab, M
    Zanger, UM
    PHARMACOGENETICS, 2000, 10 (07): : 577 - 581
  • [25] MAJOR INFLUENCE OF THE CYP2D6*41 ALLELE ON CYP2D6 METABOLIZER PHENOTYPE - A STUDY ON 1,021 VENLAFAXINE-TREATED PATIENTS
    Haslemo, T.
    Eliasson, E.
    Jukic, M.
    Ingelman-Sundberg, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 8 - 8
  • [26] A rare insertion of T-226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15
    Sachse, C
    Brockmoller, J
    Bauer, S
    Reum, T
    Roots, I
    PHARMACOGENETICS, 1996, 6 (03): : 269 - 272
  • [27] CYP2D6 metabolizer status and postoperative analgesia with tramadol
    Wilder-Smith, CH
    Wilkins, J
    ANESTHESIOLOGY, 1999, 91 (3A) : U416 - U416
  • [28] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Ayman Al-Shurbaji
    Juliette Säwe
    European Journal of Clinical Pharmacology, 2002, 57 : 877 - 881
  • [29] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Al-Shurbaji, A
    Säwe, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 877 - 881
  • [30] CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders
    Jallaq, Sahar A.
    Verba, Mark
    Strawn, Jeffrey R.
    Martin, Lisa J.
    DelBello, Melissa P.
    Ramsey, Laura B.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (01) : 56 - 62
12345